<DOC>
	<DOCNO>NCT00799799</DOCNO>
	<brief_summary>AML patient de-novo secondary disease age great 18 year eligible stem cell transplantation medical contraindication , lack donor lack stem cell , eligible . Leukemias AML M3 FAB subtype exclude study . Immunosuppressive chemotherapy prior NK cell infusion include : fludarabine cyclophosphamide 4g/m2 ( Flu/Cy ) . The therapy administer 6 day inpatient basis . Haploidentical NK cell select steady-state large volume leukapheresis product suitable KIR ligand incompatible donor . Donor-recipients pair select basis know KIR ligand . In particular , haploidentical donor include present least one allele mismatch class I locus among follow one : HLA-C allele Asn77-Lys80 , HLA-C alleles Ser77-Asn80 , HLA-Bw4 allele . Immunomagnetic enrichment NK cell follow two subsequent step : 1 ) depletion CD3+ T cell follow 2 ) positive selection CD56+ NK cell . Contaminating CD3+ T cell carefully evaluate .</brief_summary>
	<brief_title>Adoptive Immunotherapy High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells</brief_title>
	<detailed_description>When previously cryproserved NK cell still available , re-infusions may perform , accord PI 's evaluation . The number remain NK cell must sufficient reinfusion least minimum dose cell ( 106/kg ) . At least two month elapse two consecutive infusion procedure .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Signed informed consent . Performance Status ≥ 70 % ( Karnofsky score ) ≤ 2 ( WHO ) . Age great 18 year . Availability KIR incompatible haploidentical donor . Adequate renal ( serum creatinine &lt; 2 mg/dl ) , pulmonary ( Sat O2 ≥ 96 % ) hepatic ( ALT/AST &lt; 2.5 x N ) function . Patients enrol protocol must autologous graft cryopreserved reinfused case severe myelosuppression induce haploidentical NK cell . Backup cell reinfused case ANC &lt; 0.5 x 109/L day + 40 start immunosuppressive regimen . Age &lt; 18 . People unable give inform consent . HIV positivity . HCV positivity high viral load . Intercurrent organ damage medical problem would interfere therapy . Pregnant nursing female . Current uncontrolled infection . No availability cryopreserved autologous stem cell graft reinfused case severe myelosuppression . Signs symptom fluid retention ( e.g . pleural effusion )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Nk cell infusion</keyword>
	<keyword>minimal residual disease AML patient</keyword>
	<keyword>traffic NK cell infusion</keyword>
	<keyword>cytolytic effect leukemic cell</keyword>
</DOC>